JERUSALEM , Nov. 12, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces financial results for the three and nine months ended September 30, 2019 . Highlights of the third quarter 2019 and recent weeks include: Presented two posters highlighting data

  JERUSALEM , Sept. 25, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that two posters highlighting data from the Company's Phase 3 clinical development program for the Accordion Pill ® Carbidopa/Levodopa (AP-CD/LD), were presented yesterday at

JERUSALEM , Sept. 16, 2019 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that two posters in support of the Company's Phase 3 clinical development program for the Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD), will be presented at the

JERUSALEM , Sept. 3, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Company management will participate at the following upcoming investment conferences in September. HC Wainwright 21 st Annual Global Investment Conference Date: September

JERUSALEM , Aug. 9, 2019 /PRNewswire/ --  Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces financial results for the three and six months ended June 30 , 2019.   Highlights of the second quarter 2019 and recent weeks include: Completed the qualification studies for the

Conference Call to begin at 8:30 am ET JERUSALEM , July 22, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces top-line data from the Company's pivotal Phase 3 trial (the ACCORDANCE trial) evaluating the safety and efficacy of the Accordion Pill ®

Peer-reviewed journal article highlights unique oral delivery platform's ability to enhance pharmacokinetic and therapeutic benefit for challenging drugs JERUSALEM , July 1, 2019 /PRNewswire/ --   Intec Pharma Ltd.  (NASDAQ: NTEC) (" Intec " or "the Company") today announced that a review

Accordion Pill demonstrated more stable levodopa concentrations and significantly reduced OFF time in Parkinson's disease patients JERUSALEM , June 25, 2019 /PRNewswire/ ---  Intec Pharma Ltd.  (NASDAQ: NTEC) (" Intec " or "the Company") today announces that results from an earlier Phase 2 clinical

JERUSALEM , June 19, 2019 /PRNewswire/ -- Intec Pharma Ltd.  (NASDAQ: NTEC) (" Intec " or "the Company") today announced that results from a pharmacokinetics (PK) study of the Accordion Pill™-Carbidopa/Levodopa (AP-CD/LD) 50/500 mg dosed three times per day (TID) were highlighted yesterday in a

JERUSALEM , May 28, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Company management will participate at the following upcoming investment conferences in June.  Jefferies Global Healthcare Conference Date: June 4-7, 2019 Company